The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

157 Fecal Loss of Infliximab As a Cause of Lack of Response in Severe Inflammatory Bowel Disease

(2015) Johannan F Brandse et al.   GASTROENTEROLOGY

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

(2014) B. G. Levesque et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease

(2013) Yi-Lin Chiu et al.   INFLAMMATORY BOWEL DISEASES

A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers

(2013) Jeeyun Lee et al.   PLoS One

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

(2012) Shui-Long Wang et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients

(2011) Phillip Kim et al.   Proteome Science

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis

(2009) Trine Olsen et al.   CYTOKINE